Danaher Corporation (DHR)vsNeoGenomics Inc (NEO)
DHR
Danaher Corporation
$196.22
-0.16%
HEALTHCARE · Cap: $125.93B
NEO
NeoGenomics Inc
$15.88
+3.99%
HEALTHCARE · Cap: $1.88B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 3266% more annual revenue ($25.11B vs $745.97M). DHR leads profitability with a 16.0% profit margin vs -13.3%. DHR appears more attractively valued with a PEG of 1.15. DHR earns a higher WallStSmart Score of 66/100 (B-).
DHR
Strong Buy66
out of 100
Grade: B-
NEO
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.7%
Fair Value
$117.88
Current Price
$196.22
$78.34 premium
Margin of Safety
+77.5%
Fair Value
$50.82
Current Price
$15.88
$34.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
DHR profiles as a mature stock while NEO is a turnaround play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.74 — expect wider price swings.
NEO is growing revenue faster at 11.1% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 46/100), backed by strong 16.0% margins. NEO offers better value entry with a 77.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?